News for AnaptysBio, Inc. (ANAB)

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA re

**media[552860]**

**media[552854]**

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) —

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently expanded its holdings in Eton Pharmaceuticals Inc by acquiring an additional 583,3

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Aadi Bioscience Inc. On December 31,

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc. GILD rose sharply during Wednesday's s...

AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, Wednesday announced positive data from Phase 2b RENOIR study of rosnilimab for the treatment of rheumatoid arthritis (RA).

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, showing efficacy & safety. Read more here.

Virginia-based Spire Global, Inc. (SPIR) is down over 52 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statist

**media[538162]**

PR NewswireWASHINGTON and SAN DIEGO, Feb. 3, 2025 Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda

Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.